CAFC

Editas Medicine Announces First Quarter 2024 Results and Business Updates

Retrieved on: 
среда, мая 8, 2024

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.
  • “We made significant progress in all three pillars of our strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • ET to provide and discuss a corporate update and financial results for the first quarter of 2024.
  • To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Canadian Anti-Fraud Centre supports OPP in major grandparent fraud investigation

Retrieved on: 
четверг, апреля 18, 2024

This is at least the third major investigation since 2021 resulting in the arrest of individuals behind this type of fraud.

Key Points: 
  • This is at least the third major investigation since 2021 resulting in the arrest of individuals behind this type of fraud.
  • The OPP arrests highlight that these frauds are carried out by serious and organized fraud groups based in Québec and national in scope.
  • The CAFC supported this investigation by linking and sharing fraud reports from victims across Canada and from law enforcement partners with the OPP.
  • Since 2021, Canadian police arrested more than 70 money mules picking up money at victim residences in every province.

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Retrieved on: 
понедельник, апреля 1, 2024

Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents.

Key Points: 
  • Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents.
  • AngioDynamics will also make six minimum annual payments to BD of $2.5 million through February 2029, and potential additional payments if six percent (6%) of annual net sales of AngioDynamics’ port products exceed the minimum payment.
  • The parties will participate in the pending appeal before the Federal Circuit of the case titled C.R.
  • Neither party admitted any liability in connection with the settlement agreement.

FTC, Canadian Law Enforcement Agencies Cooperate on Public Outreach to Combat Cross-Border Fraud

Retrieved on: 
вторник, апреля 2, 2024

As it celebrates Fraud Prevention Month, the Federal Trade Commission is joining with consumer protection and law enforcement agencies from the United States and Canada to engage in public outreach aimed at combatting fraud.

Key Points: 
  • As it celebrates Fraud Prevention Month, the Federal Trade Commission is joining with consumer protection and law enforcement agencies from the United States and Canada to engage in public outreach aimed at combatting fraud.
  • The agencies make up a working group of law enforcement agencies, known as the Quebec Strategic Partnership, who partner to identify and combat cross-border fraud, such as imposter, investment, and prize winnings scams.
  • Postal Inspection Service, U.S. Secret Service, Canadian Anti-Fraud Centre, Canada Post, Canada Revenue Agency, and several local police departments in Quebec.
  • In 2023, Canadian consumers submitted the second highest number of reports to the FTC from outside the United States about fraud.

FTC, Canadian Law Enforcement Agencies Cooperate on Public Outreach to Combat Cross-Border Fraud

Retrieved on: 
вторник, апреля 2, 2024

As it celebrates Fraud Prevention Month, the Federal Trade Commission is joining with consumer protection and law enforcement agencies from the United States and Canada to engage in public outreach aimed at combatting fraud.

Key Points: 
  • As it celebrates Fraud Prevention Month, the Federal Trade Commission is joining with consumer protection and law enforcement agencies from the United States and Canada to engage in public outreach aimed at combatting fraud.
  • The agencies make up a working group of law enforcement agencies, known as the Quebec Strategic Partnership, who partner to identify and combat cross-border fraud, such as imposter, investment, and prize winnings scams.
  • Postal Inspection Service, U.S. Secret Service, Canadian Anti-Fraud Centre, Canada Post, Canada Revenue Agency, and several local police departments in Quebec.
  • In 2023, Canadian consumers submitted the second highest number of reports to the FTC from outside the United States about fraud.

Fraud Prevention Month 2024: Fighting fraud in the digital era

Retrieved on: 
четверг, февраля 29, 2024

If you have information about deceptive marketing practices, report it to the Competition Bureau .

Key Points: 
  • If you have information about deceptive marketing practices, report it to the Competition Bureau .
  • In 2023, the top three most reported types of fraud were identity fraud, service fraud, and phishing –all designed to get you to pay or give away sensitive information like your social insurance number, passwords or banking details.
  • In 2023, the CAFC received 116,403 reports which included at least 41,873 victims of fraud.
  • As fraud continues to evolve we want to remind Canadian to remain vigilant by recognizing, rejecting, and reporting fraud."

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

Retrieved on: 
четверг, января 25, 2024

The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA.

Key Points: 
  • The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA.
  • The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.
  • As communicated by the tentative approval to treat PAH, YUTREPIA has already met the regulatory standards for quality, safety and efficacy.
  • In July 2023, Liquidia filed an amendment to its New Drug Application for YUTREPIA, seeking to add PH-ILD to the label.

DSS Inc. Wins Patent Dispute with Nichia Corporation

Retrieved on: 
вторник, ноября 14, 2023

NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unan​i​mous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No.

Key Points: 
  • NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unan​i​mous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No.
  • 6,879,040 (the ‘040 Patent).
  • The CAFC appeal mounted by Nichia Corp., a Japanese electronics company, asserted that a 2021 Inter Partes Review (IPR) decision by the USPTO Patent Trial and Appeal Board declaring the ‘040 Patent to be valid should be overturned.
  • The arguments put forth by Nichia were soundly defeated by the Board in 2021 and now, again, by the CAFC.

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
вторник, ноября 7, 2023

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023

Key Points: 
  • Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023
    PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024
    MORRISVILLE, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30, 2023.
  • ET to discuss the financial results and provide a corporate update.
  • Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022.
  • Total other expense, net was $0.9 million for the three months ended September 30, 2023, compared with $0.3 million for the three months ended September 30, 2022.

Indigenous Youth Need Better Support System in Transition to Adulthood

Retrieved on: 
вторник, сентября 26, 2023

Children and youth in kin care report better mental health than the foster care population.

Key Points: 
  • Children and youth in kin care report better mental health than the foster care population.
  • Kin care is where an Indigenous child or youth is cared for by their family or home community.
  • Public and private groups should allocate long-term funding that helps Indigenous child and family well-being agencies offer programs to individuals beyond entering adulthood.
  • Policy-makers should rethink provincial guidelines for program eligibility to ensure that youth get the support they need during critical life transitions.